• PsyBio Therapeutics Corp. (PSYB) has closed the second tranche of a non-brokered private placement
  • Under the second tranche, the company issued 5,533,785 for gross proceeds of $276,689
  • Together with the first tranche, the company has raised gross proceeds of $909,970
  • PsyBio Therapeutics is an intellectual property-driven biotechnology company
  • Psybio Therapeutics Corp. (PSYB) opened trading at C$0.07

PsyBio Therapeutics Corp. (PSYB) has closed the second tranche of a non-brokered private placement.

Under the second tranche, the company issued 5,533,785 units priced at $0.05 per unit for gross proceeds of $276,689. Together with the first tranche, the company has raised gross proceeds of $909,970.

Each unit consists of one subordinate voting share and one common share purchase warrant exercisable at $0.10 per share for 24 months.

Warrants are subject to an acceleration clause.

All securities issued are subject to a statutory four-month hold period.

PsyBio Therapeutics is an intellectual property-driven biotechnology company developing psycho-targeted therapeutics to improve mental health and neurological conditions.

Psybio Therapeutics Corp. (PSYB) opened trading at C$0.07.


More From The Market Online

Homeland Security certifies Xtract One for terrorism prevention

The U.S. Department of Homeland Security qualifies Xtract One's (TSX:XTRA) Gateway patron-screening portfolio as anti-terrorism technology.

Gatekeeper scores strongest Q2 financial results in its history

Gatekeeper Systems Inc. (TSXV:GSI) delivered a record-breaking fiscal Q2 2024, collecting more year-over-year growth.

Greenway Cannabis notches global cannabis accreditation

Greenway Greenhouse Cannabis (CSE:GWA) receives CUMCS-G.A.P and GACP certification for its cultivation facility in Ontario.
Fobi AI Canadian equestrian Kassidy Keith

Fobi AI to sponsor Canadian equestrian Kassidy Keith

Fobi AI (TSXV:FOBI), an AI and data intelligence stock, inks a two-year sponsorship agreement with Canadian equestrian Kassidy Keith.